Equity Profile

CAI

Caris Life Sciences, Inc.

Health CareBiotechnology$4.7B

Feb15Tue

Pre-Earnings Brief

UpcomingQ2-2026After Close9:00 AM EST

Company Snapshot

Caris Life Sciences, Inc. operates in the biotechnology sector, focusing on precision medicine and advanced molecular profiling....

Key Metrics to Watch

Revenue Growth

This quarter's revenue growth will indicate how well Caris is expanding its market presence and demand for its services.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CAI Q2-2026 Earnings Preview

Context

Company Snapshot

Caris Life Sciences, Inc. operates in the biotechnology sector, focusing on precision medicine and advanced molecular profiling. Their work is crucial for developing personalized treatment plans for cancer patients, which is a growing area in healthcare as the demand for targeted therapies increases.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In the last quarter, Caris reported an EPS of $0.00, surprising analysts who expected a loss of $0.02. The stock reacted positively, gaining 3.71% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Investors are cautiously optimistic ahead of the earnings report, given Caris's strong track record of beating EPS estimates in recent quarters. However, the lack of specific guidance may lead to uncertainty.

Bull Case

If Caris continues its trend of beating EPS estimates, it could signal strong operational performance and lead to a significant stock rally.

Bear Case

Conversely, if Caris fails to meet expectations or shows signs of slowing growth, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for this quarter?

Revenue growth will be a critical indicator of Caris's market performance and ability to attract new patients.

How many patients were served this quarter?

Patient volume is essential for assessing the company's operational success and future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Caris's ability to leverage its recent technological advancements in precision medicine, which could drive higher patient volume than anticipated.

Supporting Evidence

Caris has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in the biotechnology sector show increasing demand for personalized medicine.

Key Risk

If patient volume exceeds 10,000 this quarter, it could significantly alter market perceptions of Caris's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Caris's ability to maintain growth in a competitive biotechnology landscape.

Bull Confirmed If

A revenue growth rate of over 15% would confirm the bull case and indicate strong market demand.

Bear Confirmed If

A decline in patient volume or negative revenue growth would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.61%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±7.6% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

90.5%

Calls (60K)P/C Ratio: 0.04Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.7%, with a raw directional average of +3.0% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations, history suggests a potential stock increase of around 0.82%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess future growth.

Miss

If Caris misses expectations, the stock could drop significantly, with historical patterns suggesting a decline of around 6.32%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new partnerships or collaborations that could enhance patient access.
2Details on technological advancements in molecular profiling.
3Insights into competitive positioning within the biotechnology sector.
4Management's outlook on future revenue growth and patient volume.
5Responses to any challenges faced in the current market environment.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Scorpio Tankers Inc.

Company Snapshot

Caris Life Sciences, Inc. operates in the biotechnology sector, focusing on precision medicine and advanced molecular profiling....

Key Metrics to Watch

Revenue Growth

This quarter's revenue growth will indicate how well Caris is expanding its market presence and demand for its services.

N/A

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CAI Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

88%

Avg EPS Surprise

+541.94%

Avg Stock Reaction

+1.24%

Last Quarter Recap

In the last quarter, Caris reported an EPS of $0.00, surprising analysts who expected a loss of $0.02. The stock reacted positively, gaining 3.71% the next day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Bull Case

If Caris continues its trend of beating EPS estimates, it could signal strong operational performance and lead to a significant stock rally.

Bear Case

Conversely, if Caris fails to meet expectations or shows signs of slowing growth, it could lead to a sharp decline in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected revenue growth for this quarter?

Revenue growth will be a critical indicator of Caris's market performance and ability to attract new patients.

How many patients were served this quarter?

Patient volume is essential for assessing the company's operational success and future revenue potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may underestimate Caris's ability to leverage its recent technological advancements in precision medicine, which could drive higher patient volume than anticipated.

Supporting Evidence

Caris has consistently beaten EPS estimates, indicating strong operational execution.

The options market is pricing a larger move than historical averages, suggesting heightened expectations.

Recent trends in the biotechnology sector show increasing demand for personalized medicine.

Key Risk

If patient volume exceeds 10,000 this quarter, it could significantly alter market perceptions of Caris's growth potential.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance will hinge on Caris's ability to maintain growth in a competitive biotechnology landscape.

Bull Confirmed If

A revenue growth rate of over 15% would confirm the bull case and indicate strong market demand.

Bear Confirmed If

A decline in patient volume or negative revenue growth would support the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±7.61%

Historical Avg

±5.6%

Pricing rich

The options market is pricing in a significant move, suggesting that traders expect volatility around the earnings announcement.

Options are pricing ±7.6% while CAI has averaged ±5.6% over the last 4 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

90.5%

Calls (60K)P/C Ratio: 0.04Puts (1K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Caris beats expectations, history suggests a potential stock increase of around 0.82%, confirming strong operational performance.

In-Line / Cautious

If results are in line with expectations but lack strong guidance, the stock may see muted movement as investors reassess future growth.

Miss

If Caris misses expectations, the stock could drop significantly, with historical patterns suggesting a decline of around 6.32%.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new partnerships or collaborations that could enhance patient access.
2Details on technological advancements in molecular profiling.
3Insights into competitive positioning within the biotechnology sector.
4Management's outlook on future revenue growth and patient volume.
5Responses to any challenges faced in the current market environment.